Human Serum Contains a Protease That Protects against Cytotoxic Activity of Bacillus anthracis Lethal Toxin In Vitro

ABSTRACT The role of innate immunity in the host response to Bacillus anthracis is poorly understood. We found that normal human serum contains an antitoxin mechanism that is capable of protecting macrophages in vitro from B. anthracis lethal toxin-mediated killing. This protective activity was limited to defined amounts of toxin and was lost by heat treatment or serum dilution. Some person-to-person variation in the protective activity of serum was noted, especially with higher concentrations of lethal toxin. A similar protective activity was found in murine serum, though human serum consistently neutralized more toxin than did murine serum. The protective activities of both murine and human sera correlated with cleavage of the protective antigen into two fragments with approximate molecular sizes of 20 and 50 kDa that were recognized by the monoclonal antibodies 7.5G and 10F4, respectively. This pattern of fragmentation is consistent with cleavage at multiple sites, including the furin-susceptible site. Cleavage was abolished by heat treatment and calcium chelation. These findings highlight a potential role for serum proteases in protection against the lethal toxin of B. anthracis.

[1]  M. Willingham,et al.  Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage. , 2008, Microbial pathogenesis.

[2]  J. Pirkle,et al.  Detection and quantification of anthrax lethal factor in serum by mass spectrometry. , 2007, Analytical chemistry.

[3]  S. Leppla,et al.  Anthrax Protective Antigen Cleavage and Clearance from the Blood of Mice and Rats , 2007, Infection and Immunity.

[4]  James R. Baker,et al.  Mucosal Immunization with a Novel Nanoemulsion-Based Recombinant Anthrax Protective Antigen Vaccine Protects against Bacillus anthracis Spore Challenge , 2007, Infection and Immunity.

[5]  W. Keitel,et al.  Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. , 2006, Vaccine.

[6]  A. Casadevall,et al.  A Monoclonal Antibody to Bacillus anthracis Protective Antigen Defines a Neutralizing Epitope in Domain 1 , 2006, Infection and Immunity.

[7]  G. Georgiou,et al.  Detection of Anthrax Toxin in the Serum of Animals Infected with Bacillus anthracis by Using Engineered Immunoassays , 2006, Clinical and Vaccine Immunology.

[8]  M. Mayo,et al.  Pathophysiological Manifestations in Mice Exposed to Anthrax Lethal Toxin , 2005, Infection and Immunity.

[9]  T. Nam,et al.  The Complement Component C1s Is the Protease That Accounts for Cleavage of Insulin-like Growth Factor-binding Protein-5 in Fibroblast Medium* , 2000, The Journal of Biological Chemistry.

[10]  S. Diment,et al.  Destructive proteolysis by cysteine proteases in antigen presentation of ovalbumin , 1995 .

[11]  G. Rodriguez,et al.  Destructive proteolysis by cysteine proteases in antigen presentation of ovalbumin , 1995, European journal of immunology.

[12]  K. Klimpel,et al.  The chymotrypsin-sensitive site, FFD315, in anthrax toxin protective antigen is required for translocation of lethal factor. , 1994, The Journal of biological chemistry.

[13]  K. Rock,et al.  Serum proteases alter the antigenicity of peptides presented by class I major histocompatibility complex molecules. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Ezzell,et al.  Serum protease cleavage of Bacillus anthracis protective antigen. , 1992, Journal of general microbiology.

[15]  S. Sakiyama,et al.  Degradation of type I and II collagen by human C1̄s , 1990 .

[16]  S. Sakiyama,et al.  Degradation of type I and II collagen by human activated C1-s. , 1990, FEBS letters.

[17]  F. Dalldorf,et al.  The pathogenesis of the lethal effect of anthrax toxin in the rat. , 1966, The Journal of infectious diseases.